Who's who in pharma and how the money is made

Biotech

Smaller, science-driven firms, often built around one platform or one promising molecule. Think of companies like Moderna before COVID made it a household name. Biotechs are typically pre-revenue and burn cash while they research. Many hope to be acquired by Big Pharma or to license their drug once it shows promise. Biotech supplies much of the industry's genuine innovation; Big Pharma supplies the money and the machinery to commercialize it.

Generics makers

Once a patent expires, generics companies (Teva, Viatris, Sun Pharma, and others) produce the same molecule far more cheaply. They did not pay for the original discovery, so they compete on price and manufacturing efficiency. Generics are essential to healthcare affordability. In the US, the large majority of prescriptions filled are generics, even though they are a small share of total drug spending.

Biosimilars are the equivalent for biologic drugs (complex medicines made in living cells, like antibodies). Because biologics cannot be copied exactly, "biosimilars" must run their own trials to prove they are highly similar. That makes them harder and costlier to produce than chemical generics, so prices fall less dramatically.

CROs and CMOs

A CROCROConversion Rate Optimization (CRO) is the systematic practice of increasing the percentage of users who complete a desired action, using data, testing, and user research.Voir la définition complète → (Contract Research Organization) runs clinical trials on behalf of a drug company. A CMO (Contract Manufacturing Organization) makes the drug. Companies like IQVIA (CROCROConversion Rate Optimization (CRO) is the systematic practice of increasing the percentage of users who complete a desired action, using data, testing, and user research.Voir la définition complète →) and Lonza (manufacturing) let both Big Pharma and small biotech outsource work rather than build everything in-house. This is the "arms dealer" business: they profit regardless of which drug wins.

Distributors and pharmacies

Drugs rarely go straight from factory to patient. In the US, three wholesalers (McKesson, Cencora, Cardinal Health) move the vast majority of medicines to pharmacies and hospitals. Pharmacies (CVS, Walgreens, Boots in the UK) dispense to patients. These players earn margins on logistics and dispensing, not on discovery.

Payers and PBMs

Someone pays. In most of the world that is a national health system (the NHS in the UK, for example). In the US, it is a mix of insurers, government programs (Medicare, Medicaid), and employers.

Sitting between payers and pharma in the US are PBMs (Pharmacy Benefit Managers), which negotiate drug prices and decide which drugs a plan will cover. The three largest (CVS Caremark, Express Scripts, OptumRx) control most of the US market and wield enormous leverage. Their rebates and formularies (the covered-drug lists) heavily influence which drugs actually sell.

How the money is actually made

Here is the core economic logic: a new drug costs a fortune to develop and almost nothing to copy.

Bringing a drug to market takes many years and, by widely cited (and debated) estimates, well over a billion dollars once you account for all the failures along the way. Treat that figure as an estimate, not gospel: methodologies vary widely.

So how does anyone recoup that? The patent.

The role of patents and exclusivity

A patent grants roughly 20 years of exclusive rights from the filing date. But the clock starts early, often before trials even begin. By the time a drug is approved and selling, maybe half that time is gone. The remaining window of exclusivity is when the company must earn back its entire investment plus profit.

Patents are not the only protection. Regulators also grant market exclusivity, a separate shield. In the US, the FDA (Food and Drug Administration, the US regulator) can grant extra years of exclusivity, including special incentives for orphan drugs (medicines for rare diseases). In Europe, the EMA (European Medicines Agency) operates similar schemes. These can extend or reinforce a drug's protected period even where patents are contested.

You can read the FDA's plain-language explanation of generic competition and exclusivity here.

Why the patent cliff terrifies Big Pharma

When exclusivity ends, generics or biosimilars flood in and price collapses. Revenue for that product can fall sharply within a year or two. Because a handful of blockbusters often drive a large share of a company's profit, losing one is an earthquake.

This is the patent cliff: a predictable date when a huge revenue stream falls off a ledge.

Real examples make it concrete:

• Lipitor (Pfizer's cholesterol drug) was once the best-selling drug in the world. When it lost US exclusivity in 2011, generic competition cut its sales dramatically.
• Humira (AbbVie) faced US biosimilar competition starting in 2023 after years of dominance.

Companies see these cliffs coming years in advance, which shapes almost everything they do.

🎬 [VIDEO: "The Patent Cliff Explained" — youtube.com — a short primer on how drug patents expire and why it reshapes pharma strategy]

What companies do about the cliff

Big Pharma responds in a few well-worn ways:

Acquire innovation. Rather than wait for their own labs, they buy biotechs with promising late-stage drugs. This is why biotech and Big Pharma are symbiotic: one invents, the other buys and scales.

Build a pipeline. A healthy company always has new drugs advancing through trials to replace those about to expire. Investors watch the pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète → closely, because it signals future revenue.

Lifecycle management. Companies develop new formulations, new dosages, or combination products, and file additional patents. Critics call the aggressive end of this "evergreening": stacking secondary patents to delay competition. It is legal but frequently litigated.

Diversify. Some spread risk across many drugs and therapy areas so no single cliff is fatal.

Following one pill through the chain

Imagine a new biologic for an autoimmune disease.

1. A biotech discovers the molecule and runs early trials.

2. Big Pharma acquires the biotech, funds large Phase 3 trials (often via a CROCROConversion Rate Optimization (CRO) is the systematic practice of increasing the percentage of users who complete a desired action, using data, testing, and user research.Voir la définition complète →), and files with the FDA and EMA.

3. Once approved, a CMO or the company's own plants manufacture it.

4. Distributors move it to pharmacies and hospitals.

5. In the US, PBMs negotiate its price and coverage; payers foot most of the bill; the patient pays a copay.

6. For roughly a decade of remaining exclusivity, the drug earns back its costs and profit.

7. At the cliff, biosimilar makers enter, prices drop, and the payer saves money.

Every arrow in that chain is a place where value (and margin) is captured by a different player. Understanding who captures what is the heart of pharma fluency.

A note on pricing

Drug pricing is genuinely complex and politically charged. The list price is rarely what anyone pays: rebates, discounts, and PBM negotiations mean the "net price" can be far lower. US drug pricing policy continues to evolve, including Medicare's authority to negotiate prices for certain drugs under legislation passed in the 2020s. If you take one thing away: never assume a headline price reflects actual economics.

Key Takeaways

• Pharma is a relay, not a solo sport. Biotech innovates, Big Pharma scales and sells, CROs and CMOs do outsourced work, distributors and pharmacies deliver, and payers and PBMs decide what gets paid for.
• The whole model rests on temporary monopoly. Patents and regulatory exclusivity give a limited window to recoup enormous, failure-heavy R&D costs.
• The patent cliff is a scheduled earthquake. When exclusivity ends, generics or biosimilars crash the price, so companies buy biotechs, build pipelines, and manage lifecycles to survive it. Lipitor and Humira are the classic cases.
• List price is not net price. In the US especially, rebates and PBM negotiation mean headline numbers rarely reflect what is actually paid.

*This lesson is educational and is not medical or investment advice.*